Paik S - Search Results

1

Genomics of adjuvant therapy for breast cancer.

Kim SR, Paik S. Kim SR, et al. Among authors: paik s. Cancer J. 2011 Nov-Dec;17(6):500-4. doi: 10.1097/PPO.0b013e31823e5370. Cancer J. 2011. PMID: 22157294 Review.

2

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Paik S, et al. J Clin Oncol. 1990 Jan;8(1):103-12. doi: 10.1200/JCO.1990.8.1.103. J Clin Oncol. 1990. PMID: 1967301

3

Insulin-like growth factor II mRNA expression in human breast cancer.

Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N. Yee D, et al. Among authors: paik s. Cancer Res. 1988 Dec 1;48(23):6691-6. Cancer Res. 1988. PMID: 3180080

4

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. Paik S, et al. J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70. doi: 10.1093/jnci/90.18.1361. J Natl Cancer Inst. 1998. PMID: 9747867

5

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. Fisher ER, et al. Among authors: paik s. Cancer. 1999 Aug 1;86(3):429-38. doi: 10.1002/(sici)1097-0142(19990801)86:3<429::aid-cncr11>3.0.co;2-y. Cancer. 1999. PMID: 10430251 Clinical Trial.

6

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N. Paik S, et al. J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8. doi: 10.1093/jnci/92.24.1991. J Natl Cancer Inst. 2000. PMID: 11121461

7

Incorporating genomics into the cancer clinical trial process.

Paik S. Paik S. Semin Oncol. 2001 Jun;28(3):305-9. doi: 10.1016/s0093-7754(01)90123-x. Semin Oncol. 2001. PMID: 11402440

8

HER-2 and choice of adjuvant chemotherapy in breast cancer.

Paik S, Park C. Paik S, et al. Semin Oncol. 2001 Aug;28(4):332-5. doi: 10.1016/s0093-7754(01)90127-7. Semin Oncol. 2001. PMID: 11498827 Review.

9

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Paik S, et al. J Natl Cancer Inst. 2002 Jun 5;94(11):852-4. doi: 10.1093/jnci/94.11.852. J Natl Cancer Inst. 2002. PMID: 12048273

10

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Fisher B, et al. Among authors: paik s. J Clin Oncol. 2002 Oct 15;20(20):4141-9. doi: 10.1200/JCO.2002.11.101. J Clin Oncol. 2002. PMID: 12377957 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,467 results

Search Page

Filters